{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Prothena Corporation plc"},"Symbol":{"label":"Symbol","value":"PRTA"},"Address":{"label":"Address","value":"77 SIR JOHN ROGERSON'S QUAY,BLOCK C, DUBLIN 2, D02 VK60, Ireland"},"Phone":{"label":"Phone","value":"+353 12362500"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004)."},"CompanyUrl":{"label":"Company Url","value":"https://www.prothena.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brandon S. Smith","title":"Chief Operating Officer"},{"name":"Chad J. Swanson","title":"Chief Development Officer"},{"name":"Gene G. Kinney","title":"President, Chief Executive Officer & Director"},{"name":"Wagner M. Zago","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}